↓ Skip to main content

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab

Overview of attention for article published in BMC Musculoskeletal Disorders, July 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
63 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Published in
BMC Musculoskeletal Disorders, July 2015
DOI 10.1186/s12891-015-0620-4
Pubmed ID
Authors

Mariagrazia Lorenzin, Augusta Ortolan, Paola Frallonardo, Francesca Oliviero, Leonardo Punzi, Roberta Ramonda

Abstract

The advent of anti-tumor necrosis factor-α (TNFα) drugs has changed the course of ankylosing spondylitis (AS). While data are available concerning the long term effectiveness of single anti-TNF agents, little has been published about predictors of treatment response in AS. The aim of this retrospective study was to evaluate the survival, effectiveness, and safety of infliximab over a 5-year period and to identify predictors of disease outcome. Seventy AS patients attending the Rheumatology Clinic of the University of Padua who were treated with intravenous infliximab at 0, 2, 4 weeks and then every 6, 8, or up to 16 weeks were studied retrospectively. Demographic information, laboratory inflammatory and disease indices (BASDAI, BASFI, BASMI) were collected (at baseline, 3, 6, 12 months and once a year thereafter). Clinical improvement, drug tolerability, adverse events/side effects and causes leading to discontinuation were recorded. Infliximab caused a rapid, persistent improvement at all the assessment times in the BASDAI 50 (71.4 %) and ASDAS scores (97.1 % in ASAS20, 80 % in ASAS40, 80 % in ASAS5/6), and already within 6 months of beginning treatment in 50 % percent of the patients. The other 50 % withdrew because of: adverse events (12 = 34.3 %), side effects (5 = 14.3 %), drug inefficacy (12 = 34.3 %), spontaneously (4 = 11.4 %). Those who did not respond were prevalently females (34.3 % vs 17.1 %). Factors such as female sex, use of steroids, persistently high inflammatory levels, BASFI and BASDAI indices were found to be negative predictors of treatment response. Infliximab was found to be safe, effective and well-tolerated; it elicited satisfactory long term response and drug survival rates.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 62 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 16%
Other 9 14%
Researcher 8 13%
Professor 4 6%
Student > Bachelor 4 6%
Other 13 21%
Unknown 15 24%
Readers by discipline Count As %
Medicine and Dentistry 21 33%
Nursing and Health Professions 3 5%
Computer Science 2 3%
Biochemistry, Genetics and Molecular Biology 2 3%
Engineering 2 3%
Other 11 17%
Unknown 22 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2016.
All research outputs
#15,356,841
of 22,844,985 outputs
Outputs from BMC Musculoskeletal Disorders
#2,458
of 4,046 outputs
Outputs of similar age
#153,927
of 263,458 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#39
of 59 outputs
Altmetric has tracked 22,844,985 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,046 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,458 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.